Valeant Pharmaceuticals International, Inc. (VRX) Shares Bought by Aperio Group LLC

Aperio Group LLC lifted its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 53.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 187,803 shares of the specialty pharmaceutical company’s stock after buying an additional 65,424 shares during the quarter. Aperio Group LLC owned about 0.05% of Valeant Pharmaceuticals International worth $2,691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Paulson & CO. Inc. increased its position in shares of Valeant Pharmaceuticals International by 12.5% during the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after buying an additional 2,428,900 shares during the period. Vanguard Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 4.2% during the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after buying an additional 294,643 shares during the period. CIBC World Markets Inc. increased its position in shares of Valeant Pharmaceuticals International by 2.3% during the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after buying an additional 83,592 shares during the period. Chou Associates Management Inc. increased its position in shares of Valeant Pharmaceuticals International by 29.7% during the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after buying an additional 700,000 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Valeant Pharmaceuticals International during the second quarter valued at about $41,574,000. Institutional investors own 49.74% of the company’s stock.

Several brokerages recently issued reports on VRX. Piper Jaffray Companies reiterated a “sell” rating and set a $12.00 price target on shares of Valeant Pharmaceuticals International in a research report on Friday. HC Wainwright reiterated a “hold” rating and set a $17.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday. TheStreet upgraded shares of Valeant Pharmaceuticals International from a “d” rating to a “c-” rating in a research report on Tuesday, November 7th. Royal Bank Of Canada set a $18.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “sector perform” rating in a research report on Wednesday. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $19.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday. Five research analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals International has an average rating of “Hold” and a consensus price target of $17.17.

WARNING: This piece of content was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/12/valeant-pharmaceuticals-international-inc-vrx-shares-bought-by-aperio-group-llc.html.

In related news, Director Schutter Richard U. De acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.87% of the stock is owned by corporate insiders.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at $15.38 on Friday. The firm has a market cap of $5,361.35, a P/E ratio of 2.50, a P/E/G ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $18.71. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 4.84.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply